59 results about "Autoimmune Reactions" patented technology

Based upon a strong correlation between regulator T cells (Treg cells) and suppressing or preventing a cytotoxic T cell response, provided are methods for the production of ex vivo activated and culture-expanded isolated CD4+CD25+ suppressor Treg cells for the prevention or suppression of immune reactions in a host, particularly in a human host, and including autoimmune responses. The resulting ex vivo culture-expanded Treg cells provide a sufficient amount of otherwise low numbers of such cells, having long term suppressor capability to permit therapeutic uses, including the preventing, suppressing, blocking or inhibiting the rejection of transplanted tissue in a human or other animal host, or protecting against graft vs host disease. Also provided are therapeutic and immunosuppressive methods utilizing the ex vivo culture-expanded Treg cells for human treatment, and high efficiency methods for research use.

The invention comprises a composition of matter and method of its use for the treatment of multiple sclerosis in humans. The composition is a modified anticholinergic alpha-neurotoxin. Alpha-neurotoxin solution, such as cobratoxin, is filter sterilized to remove bacteria. It is modified using H2O2. Any suitable preservative for parenteral administration can be employed such as methyl paraben, benzalkonium chloride or metacreosol. It is preferred that the composition is administered every other day or daily. The composition may be administered orally, subcutaneously, intramuscularly or intravenously. Parenterally, either subcutaneous or intramuscular injection is preferred.

Methods and apparatus are disclosed co-culturing stem cells with mononuclear cells and / or lymphocytes to modulate their function. The invention also discloses the use of stem cells to educate autoreactive immune cells as a mechanism to treat autoimmune diseases and immune disorder-related diseases, such as diabetes. In one aspect of the invention, bioreactors are disclosed for modulating lymphocytes and suppressing autoreactive T cells. The bioreactors can include a chamber having at least one positively charged and / or hydrophobic substrate surface, a population of stem cells attached to the substrate surface, an inlet conduit for introducing lymphocytes into the chamber, and an outlet conduit for extracting treated lymphocytes following co-culturing with the stem cells.

This invention relates to a method of producing an auto induced biological barrier against spermatozoids and / or other microorganisms including viruses and / or pre cancers or non invasive cancers involving the production of an autoimmune reaction in a host in need of such auto-inducement. The invention is characterized in that it comprises the steps of producing heat shock proteins inside vaginal and cervical mucosal cells and releasing said heat shock proteins into the vaginal cavity thus inducing an autoimmune response through a trigger and / or stimulation of both innate and adaptive systems and, as a consequence, the production of: a contraceptive effect through the elimination of the migration or free movement of individual or populations of spermatozoids and / or an inhibition of the maturation and / or capacitation process of the same and / or a neutralization or destruction of the same; a prophylactic effect through an elimination of the migration or free movement of individual or populations of other microorganisms including viruses and / or a neutralization or destruction of the same; a prophylactic effect against pre cancers; a therapeutic effect against non invasive cancers. The invention also relates to a device for using said method comprising a hollow body (1) provided with a heat source on the inside as well as with a means (13, 27) of removal of said hollow body from the vaginal or rectal cavity and a means (6, 8, 10) capable of exchanging heat originating from the hollow body.

An application of N-acetylaminoglucose in preparing the medicines for treating the local injury or general sympton caused by autoimmune reaction is disclosed.